Key facts

Active Substance
Influenza Virus Type A, H3N2Influenza Virus Type A, H1N1Influenza Virus Type B
Therapeutic area
Vaccines
Decision number
P/101/2008
PIP number
EMEA-000249-PIP01-08
Pharmaceutical form(s)
Nasal spray suspension
Condition(s) / indication(s)
Influenza
Route(s) of administration
Intranasal use
Contact for public enquiries

MedImmune, LLC

E-mail: dekkere@medimmune.com
Country: United States
Telephone: +1 3013984040

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

P/101/2008: European Medicines Agency decision of 3 November 2008 on the application for product specific waiver for influenza virus type A, H3N2, influenza virus type A, H1N1, influenza virus type B (EMEA-000249-PIP01-0...

How useful do you find this page?